Immediate Impact
57 standout
Citing Papers
Role of SLC7A11/xCT in Ovarian Cancer
2024 Standout
An Update on the Nitrogen Heterocycle Compositions and Properties of U.S. FDA-Approved Pharmaceuticals (2013–2023)
2024 Standout
Works of Catrin Cox being referenced
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial
2020
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Catrin Cox | 132 | 26 | 132 | 89 | 12 | 239 | |
| Sreekanth Reddy | 165 | 16 | 90 | 67 | 11 | 264 | |
| Alan Mackay | 114 | 40 | 37 | 80 | 13 | 253 | |
| Alexey Moisseev | 119 | 17 | 57 | 137 | 11 | 275 | |
| Tamara Snow | 124 | 24 | 113 | 46 | 10 | 235 | |
| Daniela Boggiani | 194 | 9 | 121 | 80 | 15 | 275 | |
| Elisa Minenza | 177 | 13 | 115 | 59 | 12 | 240 | |
| Uriel Bohn | 139 | 15 | 83 | 32 | 15 | 246 | |
| Alessandra Baldoni | 125 | 20 | 49 | 51 | 13 | 220 | |
| Florian Klinglmüller | 74 | 19 | 73 | 116 | 12 | 285 | |
| Jerome P. Richie | 93 | 38 | 152 | 91 | 10 | 270 |
All Works
Login with ORCID to disown or claim papers
Loading papers...